Year-end is where most pharma companies slip. Not because of big mistakes—but small misses in tax, filings, and documentation. In 2026, with the industry growing at 9-11%, tighter compliance matters more than ever.

Walk into any urban clinic in India today and you will hear one name migrating from endocrinology journals to dinner-table conversation: semaglutide. Since the drug's Indian patent expired on March 20, 2026, generics from Dr. Reddy's, Sun Pharma...

India's pharma sector evolves with Biopharma SHAKTI Scheme, focusing on biologics, biosimilars, and advanced therapies to boost global competitiveness and healthcare.

India’s pharmaceutical industry is shaping global healthcare, and women leaders are playing a decisive role in that growth. This Women’s Day 2026 feature highlights ten influential women leading strategy, innovation, and expansion across India’s phar

Complex generics and biosimilars are reshaping global pharma. As patents expire and demand rises, 2026 marks a turning point for innovation, competition, and access.

Pharma companies delivered mixed Q3 FY26 numbers as earnings hit markets. Some firms posted strong revenue and profit growth while others faced margin pressure. Investors reacted fast, with stocks rising or dipping based on results and outlooks.